Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million. The drug, JTX-1811, is a monoclonal antibody designed to ...

Jounce Partners, a Philadelphia nonprofit backed by M. Night Shyamalan, helps teachers bring out the best in their students by introducing them to the latest research-based teaching methods and ...

Gilead Sciences must like what it has seen in a two-year-old partnership with Jounce Therapeutics for a CCR8-targeting cancer immunotherapy – it has just agreed to take full ownership of the ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, leads the market with 99% of CTV supply coverage and 96% of overall ...

To better support media owners and buyers, Magnite offers: “The results of the Jounce study represent the culmination of the years we’ve spent building deep, strategic relationships with media ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, leads the market with 99% of CTV supply coverage and 96% of overall ...